logo
Octopus boom along England's southwest coast down to 'perfect storm'

Octopus boom along England's southwest coast down to 'perfect storm'

Yahoo17 hours ago

Octopuses, sharks and tuna that are booming in the sea around the UK could be part of a fundamental shift in the marine environment, a leading scientist has told Sky News.
Dr Simon Thomas, from the Marine Biological Association in Plymouth, said a perfect storm of factors, including climate change and overfishing, is leading to a rapid change in the species being found around the coast.
"Since 2016, you've seen a lot of our traditional fish, like cod, ling and pollock decreasing in numbers and pushing northwards," he said.
"Then we've seen other fish, especially things like bluefin tuna and blue sharks, being found in huge numbers in the water here.
"It's almost like you've seen a complete shift in the regime of the ocean."
'I've never seen anything like it'
Fishermen on the south coast of Devon and Cornwall are currently catching huge numbers of a large octopus species that is normally rare in the UK.
"I've never seen anything like it in my lifetime," said Dr Thomas.
"I've spent 40 years at sea and probably seen three or four of the big octopus over the years. Now they are seen regularly and (crab fishermen) are reporting their pots have been decimated."
The octopuses are raiding crab and lobster pots for an easy meal.
But there are so many of them, and they are so hungry, that fishermen say they are eating not only the bait and crustaceans, but also, at times, each other.
Sam Jago, skipper of the Bosloe, returned to Plymouth after a day's fishing with 11 crates of octopuses - a 400kg bonanza that could fetch almost £3,000 at market rates.
But he had just over one tub of crabs and lobsters - when normally he'd have more than a dozen.
"They crack the shell and suck everything out of it," he said.
"It's a quick buck at the moment, but who knows how long it's going to last for.
"They will stay here until they've eaten everything.
"But if the octopus go, the crab isn't going to just appear out of thin air.
"We won't have a great deal to catch."
Read more from Sky News:Trooping the Colour - see best pics
The Marine Biological Association is studying factors that could underpin the surge in octopus numbers.
The sea around the UK is around 2C warmer than normal. But in the southwest of England the temperature is 3C or even 4C above average for the time of year.
Dr Thomas said warmer waters increase survival of young octopus fry over winter, and a change to ocean currents could bring them more food.
'The ocean is changing'
Overfishing of species that would normally eat young octopuses may also mean more are surviving to adulthood.
"There is no doubt that the ocean is changing," he said.
"Fishermen are like the canaries in the coal mine, the first to see things changing out at sea."
Scientists say protecting key parts of the ocean as marine nature reserves would serve as a buffer against pressures from human activity elsewhere.
So far, 50 nations plus the EU have ratified the United Nations High Seas Treaty that commits countries to protect 30% of the ocean by 2030.
Another nine need to ratify it for it to become operational.
The UK government has said it will ratify the treaty by the end of the year.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Yahoo

time4 hours ago

  • Yahoo

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid improvements seen as early as 4 weeks Results reinforce the efficacy of Dupixent in treating both upper and lower respiratory diseases by targeting IL-4 and IL-13, two key drivers of type 2 inflammation Paris and Tarrytown, NY, June 15, 2025. Sanofi and Regeneron Pharmaceuticals, Inc. today presented positive results from the EVEREST phase 4 study of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. In the study, Dupixent (dupilumab) outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints. The data are from the first-ever presented head-to-head respiratory study with biologic medicines and were shared today in a late-breaking oral presentation at the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, Glasgow, UK. ENT Specialist, Otolaryngology, Head and Neck Surgery, Rhinology, A. Gemelli University Hospital Foundation, IRCSS, Rome, Italy, and lead investigator of the study 'Patients suffering from chronic rhinosinusitis with nasal polyps often live with the constant obstruction of their nasal passages that can lead to burdensome nasal congestion and loss of smell. What's more, a majority of these individuals also have asthma that can substantially impact their quality of life. EVEREST is the first-ever trial to demonstrate the superiority of Dupixent over Xolair on CRSwNP endpoints in patients with coexisting asthma, along with generally similar safety profiles. Together, these Dupixent outcomes provide important insights that will help guide patients and physicians through the treatment decision-making process.' In the EVEREST study, 360 adults with severe, uncontrolled CRSwNP and coexisting asthma were randomized to receive Dupixent 300 mg (n=181) every two weeks or a weight- and immunoglobulin E (IgE) level-based dosing regimen of omalizumab (n=179) every two or four weeks. Both Dupixent and omalizumab were added to background mometasone furoate nasal spray (MFNS). Primary and secondary endpoint results in CRSwNP for patients treated with Dupixent compared to omalizumab at 24 weeks were as follows with differences were seen as early as four weeks: 1.60-point superior reduction in nasal polyp size, a primary endpoint (p<0.00011) 8.0-point superior improvement in ability to identify different smells, a primary endpoint (p<0.00011). More patients on Dupixent improved above the anosmia threshold compared to omalizumab 0.58-point superior reduction in nasal congestion/obstruction, a key secondary endpoint (p<0.00011) 0.81-point superior improvement in loss of smell, a key secondary endpoint (p<0.00011) 1.74-point superior reduction in symptom severity (p<0.00011) 12.7-point difference in health-related quality of life (p<0.00012) 31.27-point difference in peak nasal inspiratory flow (p<0.00012) 1.87 difference in overall severity of rhinosinusitis (p<0.00012) Asthma endpoint results for patients treated with Dupixent compared to omalizumab at 24 weeks were as follows, with differences seen as early as four weeks: 150 mL difference in lung function (pre-bronchodilator FEV1; p=0.0032) 0.48-point difference in asthma control (p<0.00012) The safety results in the EVEREST study were generally consistent with the known safety profile of Dupixent in its approved respiratory indications, with similar overall rates of adverse events (AEs) observed between Dupixent (64%) and omalizumab (67%). Serious AEs were reported in 2% and 4% of patients treated with Dupixent and omalizumab, respectively. Additionally, AEs leading to study discontinuation were reported in 3% of Dupixent patients and 1% of omalizumab patients. About the Dupixent phase 4 studyEVEREST is a randomized, double-blind phase 4 study comparing the efficacy and safety of Dupixent to omalizumab in adults with severe, uncontrolled CRSwNP and coexisting mild, moderate, or severe asthma. During the 24-week study, patients received Dupixent 300 mg every two weeks or omalizumab 75 to 600 mg every two or four weeks, which was added to background MFNS. Omalizumab dosing was determined based on body weight and serum total IgE levels as per the approved label. All endpoints were assessed at 24 weeks. The primary endpoints assessed change from baseline in nasal polyp score (scale: 0-8) and the University of Pennsylvania Smell Identification Test (scale: 0-40). Secondary endpoints included change from baseline in nasal congestion (scale: 0-3), loss of smell (scale: 0-3), total symptom score (scale: 0-9), SNOT-22 (scale: 0-110), peak nasal inspiratory flow, and rhinosinusitis disease severity (visual analogue scale: 0-10 cm). Other endpoints assessed pre-bronchodilator forced expiratory volume over one second and the 7-item Asthma Control Questionnaire (scale: 0-6). About DupixentDupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL4 and IL13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases. Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, and chronic obstructive pulmonary disease in different age populations. More than one million patients are being treated with Dupixent globally. Dupilumab development programDupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in phase 3 studies, including chronic pruritus of unknown origin, bullous pemphigoid, and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit or follow Regeneron on LinkedIn, Instagram, Facebook or X. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYSanofi Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Le Bourhis | +33 6 75 06 43 81 | Rouault | +33 6 70 93 71 40 | Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Sanofi Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Châtelet | +33 6 80 80 89 90 | Li | +33 6 84 00 90 72 | Regeneron Media RelationsAnna Hodge | +1 914-255-6475| Regeneron Investor RelationsMark Hudson | +1 914-847-3482 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans', and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ('Regeneron' or the 'Company'), and actual events or results may differ materially from these forward-looking statements. Words such as 'anticipate,' 'expect,' 'intend,' 'plan,' 'believe,' 'seek,' 'estimate,' variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Products') and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Product Candidates') and research and clinical programs now underway or planned, including without limitation Dupixent® (dupilumab) for the treatment of chronic rhinosinusitis with nasal polyps as discussed in this press release; uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products, such as Dupixent for the treatment of chronic pruritus of unknown origin, bullous pemphigoid, lichen simplex chronicus, and other potential indications; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron's Products (such as Dupixent) and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron's Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates (including biosimilar versions of Regeneron's Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024, and its Form 10-Q for the quarterly period ended March 31, 2025. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website ( and its LinkedIn page ( Xolair® is a registered trademark of Novartis AG. 1 Statistically significant.2Nominally significant as the endpoint was not included in the multiplicity adjustment Press Release

A Mix of These Specific Foods Could Help You Avoid Chronic Disease
A Mix of These Specific Foods Could Help You Avoid Chronic Disease

Yahoo

time5 hours ago

  • Yahoo

A Mix of These Specific Foods Could Help You Avoid Chronic Disease

For the good of your health, you might want to favor a wider mix of flavonoids in your diet. These natural plant compounds – found in teas, berries, apples, and dark chocolate – have been linked to longer life and a lower risk of disease, new evidence shows. In particular, it was the broader range of flavonoids that made a difference in this research, not just the higher quantity of them. Flavonoids have previously been connected to anti-inflammatory effects in the body, and reductions in the risk of weight gain, cardiovascular disease, and vision loss. An international team of researchers analyzed data on 124,805 adults in the UK, aged 40 or over. They looked for links between the self-reported diets of the participants and their health, over several years. "We have known for some time that higher intakes of dietary flavonoids, powerful bioactives naturally present in many foods and drinks, can reduce the risk of developing heart disease, type 2 diabetes, and neurological conditions like Parkinson's," says nutritional scientist Aedín Cassidy from Queen's University Belfast in Northern Ireland. "This study is significant as the results indicate that consuming a higher quantity and wider diversity has the potential to lead to a greater reduction in ill health than just a single source." Black and green teas were the most common provider of flavonoids in the study, drunk by two-thirds of the participants. Other sources included apples, red wine, grapes, berries, dark chocolate, oranges, satsumas, and orange juice. The statistics showed that participants whose diets had the widest diversity of flavonoid foods had a lower risk of all-cause mortality, and of numerous health complications. While the data doesn't prove direct cause and effect, the strong suggestion is that mixing your flavonoids is good for you. "Flavonoid intakes of around 500 milligram a day were associated with a 16 percent lower risk of all-cause mortality, as well as around a 10 percent lower risk of cardiovascular disease, type 2 diabetes, and respiratory disease," says nutrition scientist Benjamin Parmenter from Edith Cowan University in Australia. "That's roughly the amount of flavonoids that you would consume in two cups of tea." Even when consuming the same total amount of flavonoids, those who consumed the widest diversity had even lower risk of these diseases, the researchers found. The top fifth of the participants in terms of diversity of flavonoid intake saw reductions of around 6-20 percent in the risk of conditions like type 2 diabetes, cancer, and neurodegenerative disease, compared to the bottom fifth. With that in mind, the researchers are recommending a mix of flavonoid-rich food and drink, every day. If you want to set yourself a challenge, the top flavonoid consumers in this study were snacking on 19 different types per day. "Eating fruits and vegetables in a variety of colors, including those rich in flavonoids, means you're more likely to get the vitamins and nutrients you need to sustain a healthier lifestyle," says nutrition scientist Tilman Kuhn from the Medical University of Vienna in Austria. The research was published in Nature Food. One Fitness Accessory Makes You Up to 7 Times More Likely to Stay Active Study Reveals How Much Exercise You Need Each Week to Control Blood Pressure A Toxicologist Reveals The Surprising Truth About Black Mold

Who's the real invasive species: us or them? Ecologists are rethinking urban biodiversity
Who's the real invasive species: us or them? Ecologists are rethinking urban biodiversity

Yahoo

time6 hours ago

  • Yahoo

Who's the real invasive species: us or them? Ecologists are rethinking urban biodiversity

Climate change is already having a profound impact on cities, as global urbanization pushes more and more people to live in them. The animals who cohabitate with human, whether we appreciate their presence or not, are changing too. Specifically, there's been an increase in invasive species — a term used to describe introduced organisms that bring dramatic and often destructive changes, and sometimes can drive other species to extinction. But here's the thing: Invasive species don't stop evolving themselves. Consider the infamous brown rats of New York City, which have evolved longer noses and shorter upper molar tooth rows, the better to enjoy the Big Apple's colder weather and higher-quality food. Other invasive species are adapting behaviorally, physically and genetically to life in cities as well. While invasive species pose major public health implications and can certainly affect humans' quality of life, their adaptive abilities can rival those of human migrants and pose a puzzling question: Who's the real invader here? Brian Verrelli, a professor in the Center of Biological Data Science at Virginia Commonwealth University, sees many of these questions as philosophical. "What does it mean to invade something, right?" he asked in a video interview. "What does it mean for humans to invade one area or another? Are there areas that we invade, or are humans welcome freely to move around the planet? We know that's the case in some places, and certainly not the case in others. "It's a bit of an interesting, hypocritical conversation," Verrelli added, given that "we are facilitating the movement of these organisms around the planet." Rats have invaded new continents because ships carrying them in the hold. Spiders move across continents inside our cars. And we have all literally "translocated" organisms from one place to another, Verrelli said, because we wanted to — flowers and household pets, for example. "Traveling globally, one can notice the same suite of species in many cities around the world — biological invasions creating a kind of global Cuisinart where the urban biota becomes homogeneous," Laura Meyerson, a professor at the University of Rhode Island who studies invasive species and ecological restoration, told Salon. " She cited the nearly ubiquitous tree of heaven (Ailanthus altissima), which is found in cities around the world. "This introduced tree is threatening important ancient ruins such as the Roman Colosseum. Interestingly, it is the host plant in its native range for the spotted lanternfly," an invasive pest that has recently gotten a lot of attention in North America. "Other common species in urban areas globally are Norway rats and English pigeons, both of which can spread disease," Meyerson said, along with "European starlings and the common reed (Phragmites australis), both of those being aggressive introduced species that displace native species." But Verrelli believes that if we can't exactly determine who counts as an invader, we also can't really say what's being invaded. That might sound like an abstruse philosophical argument, but he says it's a hot debate within the scientific community. "We have what are called 'stud books' for our primates at zoos all over the world," Verrelli said. "We don't count that as invasion, but we are directly facilitating that. I'm hitting this note because it very much underlies our idea of invasion and gene flow, how genetics moves around and what it means to point to an organism and say it belongs to a certain species." Verrelli has studied the spread of black widow spiders, an increasing medical health concern in cities along the West Coast. People now encounter these potentially deadly spiders, which used to be found in isolated desert areas, in urban or suburban garages and yards. "As we're altering the landscape within cities, these areas are becoming attractive to black widows," Verrelli said. "They're all around us now, so we need to be able to understand what's happening as they're moving into cities." There are important health and environmental questions about whether black widows are becoming more deadly or displacing other arachnid species, but Verrelli raises a different question: "They were here first. Are they really invading the urban area? Yes, because we plopped the urban area down in the middle of the desert." Verrelli spent nine years in Arizona, an arid environment where many organisms struggle to survive, but that has now been altered and made more hospitable by human habitation. Indeed, the American Southwest is particularly vulnerable to invasive species, including highly adaptive species that can affect human health, largely thanks to the rapid spread of urbanism — which can bring water to desert environments while also creating artificial heat islands in colder climates, and allowing tropical species to expand their ranges. Meyerson defines invasive species as "non-native species introduced either intentionally or accidentally by humans outside of their native range," while noting a crucial distinction between non-native but non-invasive species — tulips were imported to North America from Europe, for example, but do no ecological harm — and invasive ones. Most invasion scientists aim "to prevent introductions of harmful invasive species in the first place through public education, better screening tools and risk assessments," she said. But once such species are introduced, detecting and eradicating them quickly becomes the goal. If that doesn't work, the next goal is about managing and containing them, preventing further spread, and supporting native species by managing green spaces and natural habitats within the urban environment. "Urban areas can also be important stopover sites for migrating species," she added. "We need to manage these areas to help support these seasonal migrations." It's no longer reasonable, Verrelli believes, to draw a neat line between urban and wild spaces. "For a very long time, even most scientists studying urban areas as ecologists didn't really treat urban areas as 'natural' environments, because humans lived in them," he said. "That's something that I smile at, because if we don't believe humans are part of the natural world, we're in trouble. Most of our natural world is going to be consumed by humans, in which case we're ignoring a major influence on how organismal biodiversity is successful." Patterns of evolution play out in urban environments. A classic example often taught in high school biology classes is that of industrial melanism in the peppered moth, a British species tha looks, well, "peppered," with black dots on a mostly white background. There had always been occasional all-black moths, but from the mid-19th century, observers began to see more and more black moths in the industrial cities of England and Scotland. The mostly white moths stood out in the sooty environment and became easy prey for predators. Ultimately, the ones able to blend in were more likely to survive and reproduce. This is an adaptation — in evolutionary biology, a trait that arose due to natural selection. But when we casually talk about species adapting to life in the big city, that's not always what we're describing. A bear that overturns your trash can and figures out how to get your leftovers isn't "adapting"; it's just repurposing a behavior that evolved in its natural or ancestral environment. This kind of transfer of an evolutionary adaptation to a new context is called "exaptation." "It's really important that we know the difference between these two," Verrelli said. "We're not just trying to classify for the purpose of classification. If we can tell the exaptations versus the adaptations, then we are going to really understand the selective agents." Verrelli cites the work of Kristen Winchell at NYU, who has studied anoles lizards moving from forests into urban areas in Puerto Rico. In cities, she found, these lizards evolved longer legs relative to their body size, allowing them to crawl up metal pipes. That's not an exaptation, where the same structures that let them climb trees are applied to the new setting, but actual evolutionary adaptations. In Verrelli's view, understanding this difference isn't about discouraging these animals' presence, but making it easier for us and them to live in harmony and reasonable comfort. If an urban lizard can't climb up a pipe, an urban cat may select it right out of existence. "How do we design the urban environment to make them more readily livable to these organisms?" Verrelli asks. "What kind of surfaces should we be developing? What kind of areas? Where do we put light, where do we not put light?" Such questions will be "very important to understanding how organisms can move through urban environments." Sometimes our attempts to address invasive species can be counterproductive: Meyerson cites the example of the American elm, a formerly popular street tree appreciated not only for their beauty but also their hardiness under harsh urban conditions. But Dutch elm disease, an invasive fungus spread by bark beetles to which the native trees had no defense, has decimated the elm by tens of millions across the continent. "Ironically, many of these street trees were replaced by other introduced invasive species such as Norway maple or callery pear," she said, "which in turn have their own impacts." Introduced species are wreaking havoc due to similar lack of evolved defenses in the American beech, many amphibian species and North American bats of different kinds. Generalist creatures, those that can thrive in a variety of environments, will most easily adapt to city life and may go on to decimate native species. There is general agreement that we are no longer dealing with either a purely urban, human environment or a purely wild and untouched one. But while Verrelli belongs to one side in the ongoing debate among conservation biologists, the other includes those who believe cities are an incurable blight and that their spread must be reduced or reversed. His side, roughly speaking, sees urbanization as a permanent reality and harmonious biodiversity — sharing these spaces with our plant and animal relatives — as the most important goal. They see the distinction between wild spaces and urban spaces collapsing, which is happening anyway, not always harmoniously. "In understanding invasion, we need to learn more about cities," Verrelli said. "We need to learn more about invaders. We need to learn more about how they're doing, what they're doing. That's why we study things like bedbugs and black widows, because these are good models to learn about how this is happening, and because it's going to keep happening. "Instead of the idea of, let's go study things outside of cities, because this are the important areas we need to conserve, I'm on the other side. We need to study invasions in cities, because this is largely the future, whether we like it or not. As we move into the future, we're preparing a new landscape that's evolving all the time. Let's prepare biodiversity for it as well."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store